Company profile: WntResearch
1.1 - Company Overview
Company description
- Provider of anti-metastatic cancer therapies targeting WNT5A signaling. Pipeline includes Foxy-5, a peptide drug candidate that mimics WNT5A to reduce cancer cell mobility and spread (Phase I; reconstitutes Wnt-5a effects in breast cancer cells), and Box-5, a peptide in preclinical development that antagonizes Wnt-5a.
Products and services
- Anti-metastatic Therapy Development: Architects therapies for cancer patients by progressing WNT5A-modulating peptide candidates across preclinical and Phase I stages
- WNT5A-pathway-focused
- Box-5: A preclinical-phase peptide that antagonizes Wnt-5a effects, counteracting WNT5A signaling implicated in cancer cell behavior to inhibit pro-metastatic activity
- Foxy-5: A small, clinical-stage peptide drug candidate that mimics WNT5A to reduce cancer cell motility and spread, aiming to prevent metastasis and reconstitute Wnt-5a effects in breast cancer.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to WntResearch
Chinook Therapeutics
HQ: Canada
Website
- Description: Provider of precision medicines for kidney diseases, leveraging novel translational platforms and patient stratification tools. Pipeline includes Atrasentan, a selective ETA receptor antagonist in phase 3 for IgA nephropathy and phase 2 for other proteinuric glomerular diseases; Zigakibart (BION-1301), an anti-APRIL monoclonal antibody in phase 3 and phase 1/2 for IgA nephropathy; and CHK-336, an oral LDHA inhibitor in phase 1 for primary and idiopathic hyperoxaluria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chinook Therapeutics company profile →
Stemline
HQ: United States
Website
- Description: Provider of targeted oncology therapies and investigational medicines, including ELZONRIS (tagraxofusp), a CD123-directed therapy approved for BPDCN and being evaluated in AML, CMML, and myelofibrosis, and ORSERDU (elacestrant), an oral SERD approved for ER+, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Pipeline includes SL-801 (XPO1 inhibitor), SL-701 (glioblastoma immunotherapy), and Expanded Access Programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stemline company profile →
Transgene
HQ: France
Website
- Description: Provider of integrated immunotherapies to treat cancers and chronic infectious diseases, covering research, clinical batch manufacturing, and clinical trials. Portfolio includes TG4050 personalized neoantigen cancer vaccine using genetic engineering and AI; TG4001 therapeutic HPV-16 cancer vaccine; BT-001 (anti-CTLA4, GM-CSF) and TG6050 (IL-12, anti-CTLA4) oncolytic viruses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Transgene company profile →
BioImagene
HQ: United States
Website
- Description: Provider of digital pathology solutions for clinical diagnostics and drug discovery, delivering integrated hardware and software systems to acquire, view, share, manage, archive, and analyze tissue images in pathology laboratories, including IHC algorithms such as HER2, ER/PR, and p53.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioImagene company profile →
Sanarus
HQ: United States
Website
- Description: Provider of minimally invasive devices for the diagnosis and treatment of breast tumors, including the Visica treatment system for cryoablation of breast fibroadenomas; the Cassi II rotational core biopsy system, an automated hand held breast biopsy device to secure contiguous biopsy samples; and the ImarC tissue marker system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sanarus company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for WntResearch
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to WntResearch
2.2 - Growth funds investing in similar companies to WntResearch
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for WntResearch
4.2 - Public trading comparable groups for WntResearch
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →